TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21115455

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 h for 5-14 days
Number of subjects: 694

Group type: COMPARATOR
Intervention: Vancomycin plus aztreonam 1 g every 12 h for 5-14 days
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 694

Group type: COMPARATOR
Intervention: Vancomycin plus aztreonam
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil and Vancomycin plus aztreonam
Number of subjects: 694
Study: 19722444

Group type: EXPERIMENTAL
Intervention: 1-layer application of self-etching primer (Clearfil SE Bond) with no contamination (group 1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 2-layer application of self-etching primer (Clearfil SE Bond) with no contamination (group 2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SE primer, drying, saliva, and drying (group 4)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SE primer, drying, saliva, and rinsing/drying (group 5)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SE primer, drying, saliva, drying, SE primer, and drying (group 6)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SE primer, drying, saliva, rinsing/drying, SE primer, and drying (group 7)
Number of subjects: 56
Study: 17976094

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (4 grams)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Intravenous ibutilide without magnesium
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (1 to 3 grams)
Number of subjects: 229

Group type: COMPARATOR
Intervention: No adjunctive magnesium
Number of subjects: 229
Study: 14973335

Group type: EXPERIMENTAL
Intervention: Stationary-context condition (egocentric and/or allocentric coding)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moved-context condition (allocentric coding)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-context condition (egocentric condition)
Number of subjects: 0
Study: 11989569

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9376454

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 8186350

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg at breakfast
Number of subjects: 202

Group type: COMPARATOR
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 202
Study: 3285638

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg dexamethasone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nebulized saline
Number of subjects: 72
Study: 29908088

Group type: EXPERIMENTAL
Intervention: Continuous interlocking suture group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Criss-cross suture group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Postoperative flap thickness
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Days of discomfort
Number of subjects: 36
Study: 27004280

Group type: EXPERIMENTAL
Intervention: Digital impressions (DIG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional pick-up (CIG)
Number of subjects: 25
Study: 25582962

Group type: EXPERIMENTAL
Intervention: High cognitive load group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low cognitive load group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No image guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wireframe overlay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solid overlay
Number of subjects: 0
Study: 24026991

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with wavelength of 78 nm and 2.5 j/cm2, two times a week for 5 min, for one month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham laser therapy
Number of subjects: 60
Study: 20586368

Group type: EXPERIMENTAL
Intervention: Ask Me 3 pamphlet
Number of subjects: 0
Study: 19359232

Group type: EXPERIMENTAL
Intervention: Intrathecal therapy with 1 500 IU of antitetanus serum and 1.5 g of intravenous metronidazole daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment of 9 000 IU of antitetanus serum (4 500 IU cutaneously and 4 500 IU intramuscularly)
Number of subjects: 42
Study: 16176204

Group type: EXPERIMENTAL
Intervention: Repaglinide (2-9 mg/day, average 5.9 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5 mg acute exposure)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12949309

Group type: COMPARATOR
Intervention: Control formula (n = 65)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Formula with DHA (n = 65)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Formula with both ARA and DHA (n = 66)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Breastfed group (n = 80)
Number of subjects: 197
Study: 10856393

Group type: EXPERIMENTAL
Intervention: Furosemide withdrawal
Number of subjects: 32

Group type: COMPARATOR
Intervention: Furosemide continued
Number of subjects: 32
Study: 8785137

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1 MAC) during mild hypoxia (PE'O2 6.2 kPa)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1 MAC) during moderate hypoxia (PE'O2 5.7 kPa)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (1 min isocapnic hypoxia, PE'O2 6.1 kPa)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (1 min normoxic VHV)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1 MAC) during normoxic VHV
Number of subjects: 8
Study: 1354276

Group type: EXPERIMENTAL
Intervention: Ribose 60 g daily in four doses by mouth for 3 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6686117

Group type: EXPERIMENTAL
Intervention: Training at 1.05 rad X s‐1 (group S)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Training at 3.14 rad X s‐1 (group I)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Training at 5.24 rad X s‐1 (group F)
Number of subjects: 21
Study: 30913976

Group type: EXPERIMENTAL
Intervention: Rehabilitation Gaming System for aphasia
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 17
Study: 30280657

Group type: EXPERIMENTAL
Intervention: Brigatinib (180 mg once daily with a 7-day lead-in period at 90 mg)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 275

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 275
Study: 26944023

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 25188501

Group type: EXPERIMENTAL
Intervention: AOM 400 mg
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 22640674

Group type: EXPERIMENTAL
Intervention: Connecticut intrusion arch
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mini-implant system
Number of subjects: 45

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 45
Study: 19263026

Group type: EXPERIMENTAL
Intervention: Coordination Centres for Clinical Trials (KKS)
Number of subjects: 0
Study: 17957155

Group type: EXPERIMENTAL
Intervention: Probiotic formula (LGG and Bifidobacterium longum) administered during the first 6 months of life
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no probiotic administration)
Number of subjects: 37
Study: 15586515

Group type: EXPERIMENTAL
Intervention: 0.25% bupivicaine via elastomeric infusion pump (ON-Q) for 48 hours at 2 cc/h
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline solution via elastomeric infusion pump (ON-Q) for 48 hours at 2 cc/h
Number of subjects: 45
Study: 11683310

Group type: EXPERIMENTAL
Intervention: Interactive multimedia module
Number of subjects: 174

Group type: COMPARATOR
Intervention: Customary Instruction (Control)
Number of subjects: 174
Study: 9574889

Group type: EXPERIMENTAL
Intervention: Benzyl benzoate (as an additive to Acarosan)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Benzyl benzoate
Number of subjects: 118
Study: 7933267

Group type: EXPERIMENTAL
Intervention: Duplex criteria by Zwiebel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Duplex criteria by Strandness
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Peak systolic velocity > 270 cm/sec and end diastolic velocity > 110 cm/sec
Number of subjects: 120
Study: 3340474

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of MMR, DTP, and OPV vaccines
Number of subjects: 815

Group type: COMPARATOR
Intervention: Sequential administration of MMR followed by booster doses of DTP and OPV 2 months later
Number of subjects: 815
Study: 31302023

Group type: EXPERIMENTAL
Intervention: Caring efficacy training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 28599629

Group type: EXPERIMENTAL
Intervention: Methoxamine 4 μg·kg‐1·min‐1 (M3)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Methoxamine 2 μg·kg‐1·min‐1 (M1)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Methoxamine 3 μg·kg‐1·min‐1 (M2)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All groups (including M3)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: M1 and M2
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: M3
Number of subjects: 300
Study: 27421049

Group type: EXPERIMENTAL
Intervention: Home-based testing services
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HIV clinics established for TasP
Number of subjects: 9

Group type: COMPARATOR
Intervention: Linkage to HIV clinics
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Referrals to HIV clinics
Number of subjects: 9
Study: 24589564

Group type: EXPERIMENTAL
Intervention: Visceral abdominal adipose tissue (VAT)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Subcutaneous abdominal adipose tissue (SAT)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Hepatic fat fraction (HFF)
Number of subjects: 425
Study: 23040830

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study: 19536915

Group type: EXPERIMENTAL
Intervention: Additional 12-week treatment with varenicline
Number of subjects: 377581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377581
Study: 17638657

Group type: EXPERIMENTAL
Intervention: Cryoprobe-assisted lumpectomy
Number of subjects: 6
Study: 15273395

Group type: EXPERIMENTAL
Intervention: Synthetic conjugate polysaccharide vaccine against Hib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed products prepared with Hib polysaccharide extracted from bacteria
Number of subjects: 0
Study: 11136307

Group type: EXPERIMENTAL
Intervention: Diathermy incision
Number of subjects: 100

Group type: COMPARATOR
Intervention: Scalpel incision
Number of subjects: 100
Study: 10223783

Group type: EXPERIMENTAL
Intervention: 10 mg BMS‐186716
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20 mg fosinopril
Number of subjects: 9
Study: 7872185

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Enoxaparin 60 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Enoxaparin (combined 40 mg and 60 mg)
Number of subjects: 52
Study: 2309993

Group type: EXPERIMENTAL
Intervention: SULLA 808 V (Drägerwerk AG, Lübeck)
Number of subjects: 4

Group type: COMPARATOR
Intervention: AV 1 (Drägerwerk AG, Lübeck)
Number of subjects: 4

Group type: COMPARATOR
Intervention: ELSA (Gambro Engström AB, Bromma, Sweden)
Number of subjects: 4

Group type: COMPARATOR
Intervention: VIVOLEC (Hoyer Medizintechnik, Bremen)
Number of subjects: 4
Study: 359019

Group type: EXPERIMENTAL
Intervention: Tienylic acid (500 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tienylic acid and Hydrochlorothiazide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tienylic acid
Number of subjects: 11
Study: 31990615

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Community Treatment by Experts
Number of subjects: 101
Study: 30948365

Group type: EXPERIMENTAL
Intervention: Sequential high-dose chemotherapy (sHD) - 2 weekly 3-day blocks with cytarabine 2 g/m2 twice a day for 2 days plus idarubicin
Number of subjects: 574

Group type: COMPARATOR
Intervention: Standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Sequential high-dose chemotherapy (sHD)
Number of subjects: 574
Study: 28166521

Group type: EXPERIMENTAL
Intervention: Tolvaptan (daily split doses titrated to tolerance: 30/15, 45/15, 60/30, or 90/30 mg) for 12 months
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1370
Study: 26703660

Group type: EXPERIMENTAL
Intervention: 3-month evidence-based diabetes self-management intervention
Number of subjects: 65
Study: 24288221

Group type: EXPERIMENTAL
Intervention: Group A: plastic stents changed every 3 months or sooner if symptoms appeared
Number of subjects: 78

Group type: COMPARATOR
Intervention: Group B: plastic stents changed on demand at the onset of symptoms
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Group A: plastic stents changed every 3 months
Number of subjects: 78

Group type: COMPARATOR
Intervention: Group B: plastic stents changed on demand
Number of subjects: 78
Study: 21781648

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg taken orally thrice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral Diclofenac (75 mg taken orally twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diclofenac Epolamine Topical Patch (DETP, 1.3% applied topically twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Furosemide (20 mg/2 min intravenously)
Number of subjects: 40
Study: 19041216

Group type: EXPERIMENTAL
Intervention: Sedation (intermediate and definitive)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Midazolam (increasing doses)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 77
Study: 17563030

Group type: EXPERIMENTAL
Intervention: TMD + virgin olive oil
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: TMD + nuts
Number of subjects: 372

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 372
Study: 14646402

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg once a day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 22
Study: 11605698

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (2.3 g/d, 3.0 g/d, 3.8 g/d, or 4.5 g/d)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study: 9608463

Group type: EXPERIMENTAL
Intervention: Anatomic fixation (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-anatomic fixation (group B)
Number of subjects: 60
Study: 7916039

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) at 3,900 mg/m2 with cyclophosphamide (7.2 g/m2), carmustine (600 mg/m2), etoposide (2.4 g/m2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) at 3,900 mg/m2 with CBV regimen
Number of subjects: 33
Study: 1590872

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1 mg intracervically)
Number of subjects: 81
Study: 364357

Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 31589087

Group type: EXPERIMENTAL
Intervention: SENSE Theater® (experimental group, n = 44)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 77
Study: 27451978

Group type: EXPERIMENTAL
Intervention: Asparaginase (ASP) treatment
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Asparaginase (ASP) re-exposure
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Permanent insulin therapy
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Recurrent abdominal pain
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Germline DNA genotyping for ULK2 variant rs281366
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Germline DNA genotyping for RGS6 variant rs17179470
Number of subjects: 1285
Study: 25527735

Group type: EXPERIMENTAL
Intervention: Green tea (2 × 150 ml of 1% w/v tea/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 43
Study: 23620111

Group type: EXPERIMENTAL
Intervention: IMOUTA handoff method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional handoff method
Number of subjects: 0
Study: 16688105

Group type: EXPERIMENTAL
Intervention: Scaling and root planing using Odontoson M
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scaling and root planing with Odontoson M irrigated with a 10% iodised solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Curettage using Gracey curettes
Number of subjects: 60
Study: 15607620

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 568

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 568
Study: 10390663

Group type: EXPERIMENTAL
Intervention: Droperidol (5-7.5 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Midazolam (5-7.5 mg)
Number of subjects: 150
Study: 9014793

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (10 mg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1569240

Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 90 mg ketorolac
Number of subjects: 145

Group type: COMPARATOR
Intervention: 50 mg meperidine
Number of subjects: 145

Group type: COMPARATOR
Intervention: 100 mg meperidine
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: ketorolac (30 mg or 90 mg)
Number of subjects: 145
Study: 6488765

Group type: EXPERIMENTAL
Intervention: 7 proprietary corticosteroid creams
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 20
Study: 30806596

Group type: EXPERIMENTAL
Intervention: MR angiography prior to PAE (group B, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No MR angiography prior to PAE (group A, n = 50)
Number of subjects: 100
Study: 28179342

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 0
Study: 25747747

Group type: EXPERIMENTAL
Intervention: Lateral locking plate (LP group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Dual buttress plates (DP group)
Number of subjects: 86
Study: 23538267

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study: 21917117

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pseudo-electroacupuncture (placebo)
Number of subjects: 16
Study: 19352055

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Multi-daily insulin injections therapy (MDI)
Number of subjects: 64
Study: 16144857

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation (HDcit)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Heparin (HDhep)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dalteparin (HDdal)
Number of subjects: 8
Study: 12936046

Group type: EXPERIMENTAL
Intervention: Laser Doppler perfusion imager (LDPI) for assessment of hyperaemia over the interphalangeal joints in patients with rheumatoid arthritis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser Doppler perfusion imager (LDPI) for assessment of blood flow during acupuncture.
Number of subjects: 0
Study: 10632654

Group type: EXPERIMENTAL
Intervention: 40 mg extended-release cisapride
Number of subjects: 19

Group type: COMPARATOR
Intervention: 10 mg immediate-release cisapride
Number of subjects: 19
Study: 8819499

Group type: EXPERIMENTAL
Intervention: 120 mg of codeine plus placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 120 mg of codeine plus 100 mg of quinidine
Number of subjects: 16

Group type: COMPARATOR
Intervention: 100 mg of quinidine plus placebo
Number of subjects: 16
Study: 1576068

Group type: EXPERIMENTAL
Intervention: Buffered aspirin 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buffered aspirin preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin esterase activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2864935

Group type: EXPERIMENTAL
Intervention: Etilefrine pivalate (20 mg, oral administration once daily for 2-6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31706317

Group type: COMPARATOR
Intervention: Double-lumen tube (DLT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bronchial blocker (BB)
Number of subjects: 60
Study: 30800921

Group type: EXPERIMENTAL
Intervention: Computer-based learning module using PowerPoint
Number of subjects: 78
Study: 26325116

Group type: EXPERIMENTAL
Intervention: Psyllium fiber (3.5 g/day)
Number of subjects: 65
Study: 24901040

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (15 mg bupivacaine injected at L3-4)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 12
Study: 22910171

Group type: EXPERIMENTAL
Intervention: Oseltamivir-zanamivir combination therapy
Number of subjects: 543

Group type: COMPARATOR
Intervention: Oseltamivir monotherapy
Number of subjects: 543

Group type: COMPARATOR
Intervention: Zanamivir monotherapy
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Overall comparison between arms
Number of subjects: 543
Study: 20082756

Group type: EXPERIMENTAL
Intervention: Shenshi Qianghuo Dihuang Decoction (SQDD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 90